Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Co.'s late-stage clinical pipeline includes two candidates for severe genetic disorders: EDSIVO™ (celiprolol), which is a selective adrenergic modulator and a new chemical entity for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001, which is a taste-masked, immediate release formulation of sodium phenylbutyrate, designed to treat urea cycle disorders and Maple Syrup Urine Disease. We show 6 historical shares outstanding datapoints in our coverage of ACER's shares outstanding history.
Understanding the changing numbers of ACER shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACER versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACER by allowing them to research ACER shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
